Frank S. David, MD, PhD leads the biopharma consulting firm Pharmagellan, where he advises drug companies and investors on R&D and business strategy. He is also an academic researcher on strategy, regulation, and policy in the drug industry; a member of the Harvard-MIT Center for Regulatory Science; and a former blogger at Forbes.com.
I wrote
The Pharmagellan Guide to Analyzing Biotech Clinical Trials
This account of the early years of Vertex Pharmaceuticals, from its inception as a scrappy start-up to its early work in HIV, is a must-read classic for anyone interested in how science turns into new drugs. Barry Werth’s journalistic play-by-play is a cinematic, true-to-life picture of the strategic decisions, real-world challenges, and larger-than-life personalities that underlie modern drug development. His riveting follow-up, The Antidote, continues the saga by taking readers through Vertex’s pathbreaking work to transform the care of patients with hepatitis C and cystic fibrosis.
Since Nixon’s "War on Cancer," oncology treatment has seen some great advances, but also the approval of scores of over-priced drugs that do little to improve patients’ quality or quantity of life. Oncologist Vinay Prasad has written a broad, accessible overview of the flaws of modern cancer drug development that spans clinical trial design, conflicts of interest, regulatory policy, and more. His unabashedly anti-pharma stance gets preachy in places, but most of the challenges he identifies are spot-on and provide a thought-provoking roadmap for the future.
How hype, money, and bias can mislead the public into thinking that many worthless or unproven treatments are effective.
Each week, people read about new and exciting cancer drugs. Some of these drugs are truly transformative, offering major improvements in how long patients live or how they feel-but what is often missing from the popular narrative is that, far too often, these new drugs have marginal or minimal benefits. Some are even harmful. In Malignant, hematologist-oncologist Dr. Vinayak K. Prasad writes about the many sobering examples of how patients are too often failed by cancer policy and by how oncology…
The Connector's Advantage: : 7 Mindsets to Grow your Influence and Impact
by
Michelle Tillis Lederman,
Connecting matters. Your relationships make the difference in the results you achieve, the impact you have, and the speed with which you make things happen.
On top of all that, connections make you happier and healthier.
With the remote, hybrid, and global workplace as the new normal, connections―particularly diverse and…
What do we mean when we say “drug prices are too high” – and how can we fix them? In clear prose, Peter Kolchinsky, a successful biotech investor at RA Capital, clarifies the difference between list, net, and out-of-pocket drug costs, and explains how various parts of the system – drug companies, insurers, and pharmacy benefit managers (PBMs) – fit together to determine them. He also includes several detailed and timely suggestions for reform that would reduce the burden on patients and sustain biopharma innovation.
Developing life-changing drugs is risky and expensive—but that’s not what makes them unaffordable.Drug pricing is a staple of every news cycle and political debate. And while we’ve struggled for decades to agree on solutions that serve all patients without jeopardizing the invention of new medicines, many Americans suffer because they can’t afford the drugs they need.Do we really have to choose between affordability and innovation?In The Great American Drug Deal, scientist and industry expert Peter Kolchinsky answers this question with a decisive No. The pharmaceutical industry’s commitment to creating new lifesaving drugs destined to become inexpensive generics can be balanced…
A key issue about drug pricing not covered in Kolchinsky's book relates to value: even if a new therapy is affordable, is it "worth it"? Health economist Peter Neumann and his colleagues have written an authoritative, insightful, and extremely accessible history of efforts to align drugs' prices with their benefits to patients and society. This is a must-read guide for both insiders and non-experts to a topic that will be at the forefront of the drug pricing debate in the coming decade.
The US prescription drug business is a $500 billion industry whose rising prices carry profound consequences for patients, caregivers, employers and taxpayers across the nation. In the United States, average prices of leading brand-name drugs are two to four times higher than prices charged in other wealthy countries, raising questions as to what Americans are getting for the extra expense. On the other hand, healthy industry returns have arguably fueled life-saving innovation. With the advent of ever more targeted and powerful treatments, including cell- and gene-based therapies with multi-million-dollar price tags, the need for sensible drug pricing policies will only…
Everyday Medical Miracles
by
Joseph S. Sanfilippo (editor),
Frontiers of Women from the healthcare perspective. A compilation of 60 true short stories written by an extensive array of healthcare providers, physicians, and advanced practice providers.
All designed to give you, the reader, a glimpse into the day-to-day activities of all of us who provide your health care. Come…
If you're a biotech executive, investor, adviser, or entrepreneur -- or aspire to be one -- you’re supposed to understand clinical trial results. But what if you’re not an expert in study design or biostatistics? The Pharmagellan Guide to Analyzing Biotech Clinical Trials will give you the foundation you need to analyze journal articles, press releases, and investor presentations about studies of new drugs with more confidence.
In This Together explores how we can harness our social networks to make a real impact fighting the climate crisis. Against notions of the lone environmental crusader, Marianne E. Krasny shows us the power of "network climate action"—the idea that our own ordinary acts can influence and inspire those close…
